Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_683_Библиотеки_им_академика_М_И_Перельмана
.pdf
Molecular Genetics 379
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
Table45.2 Genotypephenotype correlations andmultiorgan syndromes.
Genotype (variants) Phenotype (syndromes) Comment
PRSS1 Hereditary pancreatitis Genetic counseling recommended
sev
CFTR
sev
CFTR
SPINK1/SPINK1 Familial pancreatitis Usually progresses to severe CP
bicarb
CFTR
any
CFTR
CTRC/SPINK1 RAP/CP Pancreas only– not well studied
CASR/SPINK1 RAP/CP Pancreas only– not well studied
CFTR: sev, severe mutations (typically functional class I–III); m- v, mild- variable mutations, (typically CFTR functional class IV); bicarb,
bicarbonate conductance- disrupting variant (e.g., p.R75Q); any, either severe, mild- variable, or bicarbonate- disrupting variants; CP: chronic
pancreatitis; RAP: recurrent acute pancreatitis; CBAVD: congenital bilateral absence of the vas deferens.
sev
/CFTR
m- v
/CFTR
any
/CFTR
/SPINK1 RAP/CP Pancreas only
Cystic fibrosis (CF) Manage with a CF center
Atypical CF Manage with a CF center
Pancreas/sinus/CBAVD Newly defined syndrome
The most common PRSS1 mutations are p.R122H and
p.N29I (~90%). Less common mutations include p.A16V,
p.R122C, p.N29T, p.D22G, and p.K23R. Mutations have
primarily been identified in exons 2 and 3, but rare variants have also been identified in the 5′UTR, introns 1–4,
and exons 4 and 5 (see http://www.pancreasgenetics.
org). Copy number variations of the PRSS1- PRSS2 locus
have also been associated with chronic pancreatitis[33].
SPINK1
The serine protease inhibitor, Kazal type 1 (SPINK1; PST1)
is a trypsin inhibitor secreted from pancreatic acinar cells.
Loss- of- function mutations in SPINK1 reduce its protective function and predispose to pancreatitis [34].
Mutations are found in ~2% of the population and confer
a 12- fold increased risk for pancreatitis[34]. Still, less than
1% of SPINK1 carriers develop pancreatitis. Biallelic loss
of function mutations in SPINK1 may lead to autosomal
recessive pancreatitis. However, the majority of affected
patients with SPINK1 mutations are heterozygous, indicating the presence of complex gene–gene and gene–
environment interactions[35]. For example, SPINK1 can
act as a disease modifier, and compound heterozygosity
for pathogenic variants in SPINK1/PRSS1 and, more commonly, SPINK1/CFTR has been reported[25,36].
SPINK1 mutations are detected in ~20% of patients
with idiopathic chronic pancreatitis. The most common
high- risk haplotype identified in the United States and
Europe is SPINK1 p.N34S. The SPINK1 IVS3 +2T>C
splicing variant is common in East Asian populations.
CFTR
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) are common among patients
with idiopathic chronic pancreatitis. CFTR mutations
may impair both chloride and bicarbonate conductance
(e.g., severe mutations), or only bicarbonate conductance[36,37]. Homozygosity or compound heterozygosity for two “severe” CFTR mutations generally causes
cystic fibrosis (CF), while “mild- variable” or other
mutations are associated with RAP, CP, pancreas sufficient CF and CFTR- related disorders[38]. CFTR carriers that develop pancreatitis are also likely to have an
additional genetic (e.g., SPINK1, CTRC) or other (e.g.,
pancreas divisum) risk factors[25,36]. CFTR- associated
pancreatitis is considered in Chapter4.10. The use of
CFTR modulators in pancreatic sufficient CF suggest
that specific new therapies may be available in the
future[39].
CTRC
Chymotrypsinogen C (CTRC) is a digestive enzyme and
the primary regulator of trypsin. The action of chymotrypsinogen C is twofold and dependent on calcium concentrations. In the calcium- rich duo denum, chymotryp sin
C promotes trypsinogen activation, but in solutions with
lower calcium concentrations, it mediates trypsin degradation[40]. As with SPINK1, chymotrypsin C is believed
to protect the pancreas from premature trypsin activation, with genetic defects increasing the risk of trypsinmediated pancreatitis[41,42]. Two mutations, p.R254W
and p.K247_R254del, were found to be overrepresented
in patients with idiopathic or hereditary chronic pancreatitis [41]. The c.180T>G variant has been identified in
about 10.8% of persons of European ancestry in North
America and moderately increases the risk of progression
from recurrent acute to chronic pancreatitis, particularly
in the presence of alcohol, tobacco, or PRSS1/SPINK1
mutations [43]. The independent effects of pathogenic
CTRC variants appears to be low, but they clearly increase
the risk of CP in the context of other risk factors such as

Hereditary Pancreatitis andComplex Genetic Causes
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
380
pathogenic CFTR variants [25], and can contribute to
familial clustering of CP cases.
Complex Genetics
Single- gene or Mendelian diseases are caused by highly
penetrant pathogenic mutations in a single gene that
follow a clear pattern of inheritance (e.g., autosomal
dominant, autosomal recessive). Mendelian forms of
pancreatitis, such as PRSS1- HP, are rare. Instead, most
patients have a complex etiology resulting from multiple
low- to- moderate effect risk alleles in combination with
environmental and physiologic risk factors. Complex
risk variants are defined as variants with variable effect
sizes, ranging in frequency from rare to common, that do
not cause disease in isolation. Instead, the combination
of multiple interacting risk variants and other factors
work in concert to initiate the disease process. In patients
with pancreatitis, several common risk variants have
been identified, including the CTRC c.180T>G (p.G60=)
and SPINK1 p.N43S variants (described above), a PRSS1-
PRSS2 haplotype[44], risk alleles in CLDN2[44], and the
CEL- HYB risk allele[45]. Heterozygous carriers of CFTR
variants associated with cystic fibrosis or a CFTR- related
disorder have also been associated with an increased risk
for pancreatitis as a part of a complex etiology [46].
Known risk factors for pancreatitis are outlined in the
Toxic- metabolic, Idiopathic, Genetic, Autoimmune,
Recurrent and severe acute pancreatitis and Obstructive
Pancreatitis Risk/Etiology Checklist (TIGAR- O_
V2) [27], which functions as an organizational tool to
document and track patient risk and etiological factors.
Although the identification of complex risk variants may
lend insights into a patient’s disease process, the quantification of risk to develop pancreatitis in asymptomatic
patients or to progress to severe disease in symptomatic
patients based on multiple complex variants and nongenetic factors remains challenging and imprecise.
Genetic Testing andCounseling
When a patient or family is suspicious for hereditary
pancreatitis, a (minimum) three- generation pedigree
should be collected, including family history of pancreatitis, age of onset, age at diagnosis for multiple pancreatic episodes, and pancreatic cancer [47]. Other
information valuable for assessment of a family includes
smoking and alcohol exposure, diabetes mellitus, pancreatic insufficiency, male infertility, cystic fibrosis,
chronic sinusitis, and nasal polyps [47]. Calculation of
risk in a family depends on genotype, pattern of inheritance in the family, and environmental exposures
(e.g.,tobacco, alcohol).
Indications to offer genetic testing in a symptomatic
patient include unexplained recurrent acute pancreatitis
and/or chronic pancreatitis, a first- or second- degree
relative with pancreatitis, and/or unexplained pancreatitis in a child requiring hospitalization. Genetic testing is
commercially available for several genes, including
CASR, CEL, CFTR, CLDN2, CPA1, CTRC, GGT1, PRSS1,
PRSS2, SBDS, SPINK1, and UBR1. Deletion/duplication
analysis should be considered in a proband if a mutation
is not identified from sequencing or targeted mutation
analysis.
Genetic testing should always be preceded and followed by appropriate genetic counseling. Results may
have implications for patient risk, risk to other family
members, and family planning[48]. Another concern for
genetic testing in this patient population, especially in
the United States, is insurance discrimination[48]. The
Genetic Information Nondiscrimination Act of 2008
(GINA, Pub. L, 110–233) protects against genetic discrimination in health insurance and employment in the
United States, but does not cover life, disability, or longterm care insurance. Patients and families should understand the benefits, limitations, and costs of genetic
testing before the test is ordered. Therefore, clinicians
must understand the consequences of genetic testing
and should provide counseling directly or refer patients
to a genetic counselor to obtain appropriate informed
consent.
Genetic testing in a symptomatic patient can clarify
etiology and provide information on risk for related
complications, such as pancreatic cancer. Identification
of a responsible mutation may clarify risk for family
members and provide information relevant to family
planning. PRSS1- related hereditary pancreatitis follows
an autosomal inheritance pattern, and each child of a
parent with a PRSS1 mutation, has a 50% or 1in 2 chance
to inherit the deleterious allele. About 80% of individuals
who inherit a PRSS1 mutation develop pancreatitis.
Therefore, each child of a parent with a PRSS1 mutation
has a ~40% chance of developing hereditary pancreatitis.
However, variation in penetrance and severity exists
between HP kindreds, and family history should always
guide interpretation of results and risk calculation.
Identifying a responsible genetic mutation in a family
may also expedite diagnosis of family members and prevent unnecessary evaluation for other etiologies.
Predictive genetic testing in an asymptomatic individual is available when a mutation has been identified in a
close family member. Testing for this mutation can clarify risk to develop pancreatitis and risk to descendants.
Genetic testing may also identify family members who
would benefit from lifestyle interventions to reduce risk
and severity, such as avoidance of alcohol, smoking, and
fatty foods.

References 381
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
A negative test result in a patient from a family with a
known mutation reduces but does not remove the risk
for hereditary pancreatitis. Families may share additional, unidentified risk factors that predispose to pancreatic disease. Furthermore, not all hereditary
pancreatitis- appearing families have an identifiable
mutation. In a family without an identifiable mutation,
genetic testing of asymptomatic family members will be
uninformative, and discussions of risk must be tailored
according to the presentation of disease within the
family.
Genetic Testing inChildren
The decision to pursue genetic testing in a child is the
responsibility of the parents or legal guardian. When a
References
1 Whitcomb DC, Frulloni L, Garg P etal. Chronic
pancreatitis: an international draft consensus proposal for
a new mechanistic definition. Pancreatology
2016;16:218–224.
2 Comfort MW, Steinberg AG. Pedigree of a family with
hereditary chronic relapsing pancreatitis.
Gastroenterology 1952;21:54–63.
3 Rebours V, Boutron- Ruault MC, Schnee M etal. The
natural history of hereditary pancreatitis: a national series.
Gut 2009;58:97–103.
4 Howes N, Lerch MM, Greenhalf W etal. Clinical and
genetic characteristics of hereditary pancreatitis in
Europe. Clin Gastroenterol Hepatol 2004;2:252–261.
5 Sossenheimer MJ, Aston CE, Preston RA etal. Clinical
characteristics of hereditary pancreatitis in a large family,
based on high- risk haplotype. The Midwest Multicenter
Pancreatic Study Group (MMPSG). Am J Gastroenterol
1997;92:1113–1116.
6 Sibert JR. Hereditary pancreatitis in England and Wales.
JMed Genet 1978;15:189–201.
7 Rebours V, Boutron- Ruault MC, Jooste V etal. Mortality
rate and risk factors in patients with hereditary
pancreatitis: uni- and multidimensional analyses. Am
JGastroenterol 2009;104:2312–2317.
8 Gorry MC, Gabbaizedeh D, Furey W etal. Mutations in
the cationic trypsinogen gene are associated with
recurrent acute and chronic pancreatitis. Gastroenterology
1997;113:1063–1068.
9 Amann ST, Gates LK, Aston CE etal. Expression and
penetrance of the hereditary pancreatitis phenotype in
monozygotic twins. Gut 2001;48:542–547.
10 Bellin MD, Freeman ML, Schwarzenberg SJ etal. Quality
of life improves for pediatric patients after total
pancreatectomy and islet autotransplant for chronic
pancreatitis. Clin Gastroenterol Hepatol 2011;9:793–799.
child is 7 years or older, the child should provide assent
for genetic testing. Testing of a symptomatic child can
explain or confirm the diagnosis of pancreatitis and prevent unnecessary further evaluations.
Predictive genetic testing for hereditary pancreatitis is
generally not recommended for patients less than 16
years of age. There are no clear medical benefits to identifying asymptomatic carriers at a young age and waiting
to pursue testing gives the patient the opportunity to
make an informed adult decision. Predictive testing to
identify children that would benefit from diet, lifestyle,
medication, or surveillance interventions has been advocated[49]. However, avoidance of pancreatitis risk factors, particularly fatty foods, alcohol, tobacco, and stress,
are advised for all children regardless of mutation
status.
11 Bellin MD, Whitcomb DC, Abberbock J etal. Patient and
disease characteristics associated with the presence of
diabetes mellitus in adults with chronic pancreatitis in
theUnited States. Am J Gastroenterol 2017;112:
1457–1465.
12 Goodarzi MO, Nagpal T, Greer P etal. Genetic risk score
in diabetes associated with chronic pancreatitis versus
type 2 diabetes mellitus. Clin Transl Gastroenterol
2019;10:e00057.
13 Lowenfels A, Maisonneuve P, DiMagno E etal. Hereditary
pancreatitis and the risk of pancreatic cancer. J Natl
Cancer Inst 1997;89:442–446.
14 Shelton CA, Umapathy C, Stello K etal. Hereditary
pancreatitis in the United States: survival and rates of
pancreatic cancer. Am J Gastroenterol 2018;113:
1376–1384.
15 Lowenfels AB, Maisonneuve P, Whitcomb DC etal.
Cigarette smoking as a risk factor for pancreatic cancer in
patients with hereditary pancreatitis. J Am Med Assoc
2001;286:169–170.
16 Aslanian HR, Lee JH, Canto MI. AGA clinical practice
update on pancreas cancer screening in high- risk
individuals: expert review. Gastroenterology 2020;
159:358–362.
17 Uomo G, Talamini G, Rabitti PG. Antioxidant treatment in
hereditary pancreatitis. A pilot study on three young
patients. Dig Liver Dis 2001;33:58–62.
18 Chinnakotla S, Radosevich DM, Dunn TB etal. Long- term
outcomes of total pancreatectomy and islet auto
transplantation for hereditary/genetic pancreatitis. J Am
Coll Surg 2014;218:530–543.
19 Chinnakotla S, Beilman GJ, Dunn TB etal. Factors
predicting outcomes after a total pancreatectomy and islet
autotransplantation lessons learned from over 500 cases.
Ann Surg 2015;262:610–622.

Hereditary Pancreatitis andComplex Genetic Causes
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
382
20 Ulrich CD, Consensus Committees of the European
Registry of Hereditary Pancreatic Diseases MMCPSGIAoP. Pancreatic cancer in hereditary pancreatitis:
consensus guidelines for prevention, screening and
treatment. Pancreatology 2001;1:416–422.
21 Bellin MD, Freeman ML, Gelrud A etal. Total
pancreatectomy and islet autotransplantation in chronic
pancreatitis: recommendations from PancreasFest.
Pancreatology 2014;14:27–35.
22 Whitcomb DC, Gorry MC, Preston RA etal. Hereditary
pancreatitis is caused by a mutation in the cationic
trypsinogen gene. Nat Genet 1996;14:141–145.
23 Whitcomb DC. Genetic risk factors for pancreatic
disorders. Gastroenterology 2013;144:1292–1302.
24 Shelton CA, Whitcomb DC. Genetics and treatment
options for recurrent acute and chronic pancreatitis. Curr
Treatment Opt Gastroenterol 2014;12:359–371.
25 Rosendahl J, Landt O, Bernadova J etal. CFTR, SPINK1,
CTRC and PRSS1 variants in chronic pancreatitis: is the
role of mutated CFTR overestimated? Gut 2013;62:
582–592.
26 Chen JM, Ferec C. Genetics and pathogenesis of chronic
pancreatitis: the 2012 update. Clin Res Hepatol
Gastroenterol 2012;36:334–340.
27 Whitcomb DC, North American Pancreatitis Study G.
Pancreatitis: TIGAR-
O Version 2 risk/etiology checklist
with topic reviews, updates, and use primers. Clin Transl
Gastroenterol 2019;10:e00027.
28 Ellison MA, Spagnolo DM, Shelton C etal. Complex
genetics in pancreatitis: insights gained from a new
candidate locus panel. Pancreas 2020;49:983–998.
29 Masamune A, Kotani H, Sorgel FL etal. Variants that
affect function of calcium channel TRPV6 are associated
with early- onset chronic pancreatitis. Gastroenterology
2020;158:1626–1641.
30 Guy O, Lombardo D, Bartelt DC etal. Two human
trypsinogens. Purification, molecular properties, and
N- terminal sequences. Biochemistry 1978;17:1669–1675.
31 Geisz A, Sahin- Toth M. Sentinel acute pancreatitis event
increases severity of subsequent episodes in mice.
Gastroenterology 2021;161(5):1692–4.
32 Schnur A, Beer S, Witt H etal. Functional effects of
13rare PRSS1 variants presumed to cause chronic
pancreatitis. Gut 2014;63:337–343.
33 Chen JM, Masson E, Le Marechal C etal. Copy number
variations in chronic pancreatitis. Cytogenet Genome Res
2008;123:102–107.
34 Witt H, Luck W, Hennies HC etal. Mutations in the gene
encoding the serine protease inhibitor, Kazal type 1 are
associated with chronic pancreatitis. Nat Genet
2000;25:213–216.
35 Aoun E, Chang CC, Greer JB etal. Pathways to injury in
chronic pancreatitis: decoding the role of the high- risk
SPINK1N34S haplotype using meta- analysis. PLoS ONE
2008;3:e2003.
36 Schneider A, Larusch J, Sun X etal. Combined
bicarbonate conductance-
impairing variants in CFTR and
SPINK1 variants are associated with chronic pancreatitis
in patients without cystic fibrosis. Gastroenterology
2011;140:162–171.
37 LaRusch J, Jung J, General IJ etal. Mechanisms of CFTR
functional variants that impair regulated bicarbonate
permeation and increase risk for pancreatitis but not for
cystic fibrosis. PLoS Genet 2014;10:e1004376.
38 Bombieri C, Claustres M, De Boeck K etal. Recommendations
for the classification of diseases as CFTR-
related disorders.
JCyst Fibros 2011;10(Suppl 2):S86–102.
39 Akshintala VS, Kamal A, Faghih M etal. Cystic fibrosis
transmembrane conductance regulator modulators reduce
the risk of recurrent acute pancreatitis among adult
patients with pancreas sufficient cystic fibrosis.
Pancreatology 2019;19:1023–1026.
40 Szmola R, Sahin- Toth M. Chymotrypsin C (caldecrin)
promotes degradation of human cationic trypsin: identity
with Rinderknecht’s enzyme Y. Proc Natl Acad Sci U S A
2007;104:11227–11232.
41 Rosendahl J, Witt H, Szmola R etal. Chymotrypsin C (CTRC)
variants that diminish activity or secretion are associated with
chronic pancreatitis. Nat Genet 2008;40:78–82.
42 Beer S, Zhou J, Szabo A etal. Comprehensive functional
analysis of chymotrypsin C (CTRC) variants reveals
distinct loss- of- function mechanisms associated with
pancreatitis risk. Gut 2013;62:1616–1624.
43 LaRusch J, Lozano- Leon A, Stello K etal. The common
chymotrypsinogen C (CTRC) variant G60G (C.180T)
increases risk of chronic pancreatitis but not recurrent
acute pancreatitis in a North American population. Clin
Transl Gastroenterol 2015;6:e68.
44 Whitcomb DC, Larusch J, Krasinskas AM etal. Common
genetic variants in the CLDN2 and PRSS1risk for alcohol-
related and sporadic pancreatitis. Nat
PRSS2loci alter
Genet 2012;44:1349–1354.
45 Fjeld K, Weiss FU, Lasher D etal. A recombined allele of
the lipase gene CEL and its pseudogene CELP confers
susceptibility to chronic pancreatitis. Nat Genet
2015;47:518–522.
46 Miller AC, Comellas AP, Hornick DB etal. Cystic fibrosis
carriers are at increased risk for a wide range of cystic
fibrosis-
related conditions. Proc Natl Acad Sci U S A
2020;117:1621–1627.
47 Solomon S, Whitcomb DC. Genetics of pancreatitis: an
update for clinicians and genetic counselors. Curr
Gastroenterol Reports 2012;14:112–117.
48 Applebaum SE, O’Connell JA, Aston CE etal. Motivations
and concerns of patients with access to genetic testing for
hereditary pancreatitis. Am J Gastroenterol 2001;96:
1610–1617.
49 Ross LF, Saal HM, David KL etal. Technical report: ethical
and policy issues in genetic testing and screening of
children. Genet Med 2013;15:234–245.

46
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
Epidemiology andPathophysiology ofTropical Chronic Pancreatitis
Shailesh V. Shrikhande1 and Savio G. Barreto
1
Gastrointestinal and Hepato- Pancreato- Biliar y Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
2
Division of Surgery and Perioperative Medicine, Flinders Medical Centre, Adelaide, South Australia, Australia
3
College of Medicine and Public Health, Flinders University, South Australia, Australia
2,3
383
Introduction
In 1937, Kini[1] published a report on chronic calcific
pancreatitis from India. Similar findings in autopsy studies were reported from southern India in 1954[2]. While
the features presented in those report were strikingly
similar to the report on 45malnourished patients from
Indonesia published a couple of decades later, the credit
for describing tropical (chronic) pancreatitis (TCP) as a
distinct entity rests with Zuidema[3,4]. These patients
were from economically weaker sections and were suffering from protein calorie malnutrition.
GeeVarghese [5,6] provided a detailed description of
features that constituted TCP based on his analysis of
patients in Kerala, southern India. This body of work
now forms the framework on the basis of which our
understanding of TCP resides.
TCP is considered a distinct subtype of CP comprising calcifying, nonalcoholic CP afflicting younger, generally malnourished individuals from the tropical
regions of Asia[7–11], Africa[12–15], and even South
America [16,17]. A male predominance was also
noted[18–20]. However, there has been the occasional
report of the disease from developed nations more
often due to diagnosis of the disease in migrants arriving from the developing world [21]. In the past, the
entity has been referred to by numerous terminologies
including tropical calcific pancreatitis, tropical pancreatic diabetes, nutritional pancreatitis, juvenile pancreatitis syndrome, Afrocalculous pancreatopathy, and fibrocalculous pancreatopathy, or fibrocalculous pancreatic diabetes (FCPD).
However, the terminology most commonly employed
today is TCP [22,23]. GeeVarghese summarized the
Asian pancreatitis, tropical
natural history of TCP in the adage, “recurrent abdominal pain in childhood, diabetes around puberty and
death at the prime of life”[5]. Barman and colleagues
presented the triad of symptoms that comprised TCP,
namely, abdominal pain, maldigestion and steatorrhea,
and diabetes mellitus[24].
To date, there remains a paucity of large- scale epidemiological data on the prevalence of TCP. A field study from
Kerala in southern India, involving 28,567 inhabitants,
determined the prevalence of TCP to be 1 : 793 in that
region[8] based on well laid out criteria for diagnosis of the
disease. The study revealed that contrary to previous hospital reports, TCP in Kerala appeared to have a female preponderance (male: female ratio of 1 : 1.8), older age at
disease onset (mean 23.9 yr), and evidence of milder
disease. Prior attempts at understanding the nature of
thedisease had included hospital studies and a couple of
monographs published by GeeVarghese[5,22] based on his
experience of more than 1500 patients with the disease.
The criticism by Balaji etal.[8] of these prior studies was
the possibility that their findings were potentially influenced by need for healthcare (patients presenting only
when symptomatic) as well as access to healthcare being
preferentially available to males.
A large nationwide study from India that included
1086 CP patients has determined that idiopathic CP is
now the most common subtype of the disease in the
country (accounting for 60% of cases)[25]. This finding
is not too dissimilar from the 70% of patients from India
and China labeled to have idiopathic CP based on a survey in the Asia- Pacific region[9]. Interestingly, in the
study by Balakrishnan etal.[25], when well- defined criteria for TCP were applied, TCP was found in only 3.8%
of patients. The authors conjectured that these findings
The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery, Fourth Edition. Edited by Hans G. Beger, Markus W. Büchler,
RalphH. Hruban, Julia Mayerle, John P. Neoptolemos, Tooru Shimosegawa, Andrew L. Warshaw, David C. Whitcomb, and Yupei Zhao.
© 2023 John Wiley & Sons Ltd. Published 2023 by John Wiley & Sons Ltd.
Companion website: www.wiley.com/go/beger/thepancreas4e

Epidemiology andPathophysiology ofTropical Chronic Pancreatitis
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
384
may reflect a prior overrepresentation of the disease
owing to the interchangeable use of the terms idiopathic CP and TCP with the possibility that the true
incidence of TCP lies somewhere in between this wide
variation. The declining incidence of TCP has been
noted in other studies from India, too[26,27]. Whether
this is a reflection of improving socioeconomic conditions accompanied by improved nutrition [25,28], an
increase in smoking and alcohol consumption amongst
youngsters [26], or simply a better elucidation of the
entity “idiopathic CP,” leading to more individuals fitting these criteria rather than TCP[29], may remain a
question left unanswered.
Pathophysiology
The initial documentation of cases of TCP in malnourished patients from the tropics and from financially
weaker sections of society[1,4] instinctively led researchers to focus on dietary components as a cause for the
disease[30]. Over the years, detection of TCP in apparently healthy individuals with a normal nutritional status (as per their body mass index) [31,32] has led to
micronutrient deficiency being more intensively investigated. Eloquent studies teasing out pathological
changes [33] and genetic mutations and comparing
these with other subtypes of CP have heralded a possibly
more objective approach to the understanding of the
entity[34,35].
Pathology
Gross appearance of the gland depends on the duration
of disease, degree of fibrosis, the presence of cysts, and
location and size of calculi[36]. With the passage of time,
the gland undergoes uneven fibrosis and atrophy often
leading to an eccentric ductal location [23] with the
gland often left appearing finger- like with a nodular and
irregular surface[37].
One of the hallmarks of TCP is the presence of large
calculi composed of 95.5% calcium carbonate (mainly
in the form of calcite[38]), a small amount of calcium
phosphate and traces of magnesium, urate, and oxalate
distributed throughout the ductal system varying in
color, shape, and size [23]. The calculi possess an
amorphous nidus and a cryptocrystalline periphery[39]. The biochemical and structural nature of calculi in TCP is not too dissimilar to those in other
subtypes of CP [23]. The larger stones tend to form
toward the head with their size decreasing toward the
tail region.
On microscopic examination, the hallmark of TCP is
the degree of intralobular fibrosis[33] that is uniform
throughout the pancreatic parenchyma[40]. Nair[36]
suggested that TCP was characterized by a lack of
inflammation suggesting the terminology of “tropical
calcific pancreatopathy” to be more appropriate.
However, these findings have not been corroborated by
others. Shrikhande and colleagues [33] compared the
histologic appearance of TCP versus alcoholic CP
(ACP) and idiopathic CP and uncovered similar histological features and a comparable inflammatory cell
reaction in all three subtypes of CP although the extent
of the pathological change was variable in the individual types. The degree of endophlebitis and plasma cell
density was significantly higher in TCP[33]. This finding of plasma cell infiltration of the pancreas is in
keeping with the report of Nagalotimath who also
found a lymphocyte infiltration mainly around the
ducts [37]. Cyriac and colleagues [41] have recently
demonstrated that stellate cell activation occurs in a
similar manner to other subtypes of CP. Total fatty
replacement of parenchyma has been noted to be a
striking feature in TCP, seen exclusively in diabetics
with gross atrophy of islets of Langerhans [40].
Moreover, in patients with established diabetes secondary to TCP (FCPD) histopathological examination
as well as immunohistochemistry have revealed varying extents of acinar atrophy and parenchymal destruction[23] along with paucity of alpha and beta cells and
reduction in glucagon positivity and areas of
nesidoblastosis[37,42].
An interesting observation in the pathological assessment of tissues of patients with TCP when compared with
alcoholic and idiopathic has been the increase in neural
tissue and neural alterations associated with progression
of the disease toward a stage amenable to surgery[43], a
hallmark of pain accompanying CP[44]. It is not only the
neural alterations that are identical but other histologic
aspects including the degree of endophlebitis, overall
density of plasma cells, and inflammatory cell reaction
leading to the inference that independent of the underlying etiology, the pathologic changes accompanying CP
eventually reach a common immunologic stage beyond
which CP appears to progress as a single distinctive
entity[33].
Nutrition (Including Cassava)
The initial reports of TCP originating from regions in
the developing world coupled with the clinical picture
of young emaciated patients, intuitively led clinicians
to focus on the nutritional aspect, or more specifically,
protein calorie malnutrition[4,12,45]. However, over
the years, possibly a more objective approach to investigating the role of malnutrition as a causative agent
has led pancreatologists to infer that
malnutrition, in

Pathophysiology 385
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
itself, is not the main cause for TCP[46] and the nutritionally deprived state may rather be an effect of
the malabsorption associated with disease [47,48].
Patients with kwashiorkor, do not develop features of
TCP [23,49]. Moreover, while malnutrition exists in
many other countries in the world, there are no
reported cases of TCP/FCPD from them [50], while
on the flipside TCP cases have been reported even
among patients from well- nourished families [23].
Nonetheless, cause or effect, malnutrition remains a
major issue in TCP and addressing it in its entirety
forms an essential part of the workup and management of patients with TCP[51].
While malnutrition may not be the only etiological
factor in the causation of TCP, it is very likely that micronutrient deficiency, along with varying degrees of macronutrient deficiency and oxidant stress are cofactors in
the causation of TCP.
Cassava Toxicity
Cassava (tapioca, Manihot esculenta Crantz) was implicated as a cofactor in the causation of TCP based on three
hypotheses, namely, the geographic coincidence of cassava being the staple diet of the low socioeconomic class
of people in Kerala and the high incidence of TCP
reported there [52]; the cyanogenic glycoside composition of cassava (93% linamarin and 7% lotaustralin), which
requires sulfur derived from the sulfur- containing amino
acids (such as cysteine and methionine) for its
detoxification— believed to be inherently deficient in malnourished individuals[53]; and experimental induction of
hyperglycemia on feeding cyanide to rats[30] or hypoinsulinemia and histopathological changes of necrosis,
hemorrhage, and fibrosis of the exocrine and endocrine
portions of the pancreas in dogs fed on cassava[54].
While the activity of the cyanogen detoxifying enzyme,
rhodanase, has been shown to be reduced accompanied
by a decrease in sulfur- containing amino acids and antioxidants such as glutathione in TCP patients[55], neither this study[55], nor any of the other case- control or
cohort clinical studies [49,56,57] were able to conclusively prove the role of cassava consumption in the causation of TCP. Besides, TCP has been reported even
from regions where cassava is not consumed [9,25].
Even in the experimental setting, long- term ingestion of
tapioca by rats failed to result in the development of diabetes or pancreatitis[58].
Antioxidants (Including Micronutrients)
It has been hypothesized that escalating oxidative stress
within the acinar cells as a result of cytochrome p450
superfamily induction, deficiency of micronutrients
required to maintain stores of reduced glutathione, and
exposure to bioactivated chemicals[59,60] plays a role in
the development of CP.
In TCP patients, the surrogate marker for p450I
activity, namely, theophylline clearance was found to
be faster in cases as compared to controls [61].
Additionally, the bioavailability of ascorbic acid and
beta-
carotene that predispose to pancreatic oxidative
stress was found to be significantly reduced in South
Indians (from Chennai) with TCP as compared to
patients with CP from Manchester [35]. Girish and
colleagues[62] observed enhanced lipid peroxidation
with concomitant decrease in antioxidant status in
patients with TCP as compared to healthy subjects.
Moreover, in the same study, they noted that zinc deficiency appeared to affect the oxidative status in
patients with TCP. The same group also noted a correlation between zinc deficiency and exocrine and
endocrine insufficiency in CP patients [63]. They
observed a marked effect of diabetes in zinc levels in
patients with TCP as compared to those with ACP[63].
Other postulated mechanisms by which zinc deficiency
could contribute to the progression of CP include
reduction of free radical scavengers, increased collagen deposition, and possibly an alteration in immune
function[64].
Genetics of TCP and Familial Clustering
The finding of an aggregation of patients with TCP in
certain families[65], reported as occurring in up to 8%
of TCP patients[66], raised the possibility of heredity as
another potential contributory factor to the development of TCP. However, while there has been no further
evidence to support this initial finding, the role played
by genetic mutations in important regulators of pancreatic secretion as well as the innate protective mechanisms against premature zymogen activation have been
extensively studied in patients with TCP. Table 46.1
provides a list of the most significantly proven mutations involved in the pathogenesis of TCP[34,67–74].
Mahurkar and colleagues[75] presented an interesting
model called the “two- hit model” to hypothesize the
pathogenesis of TCP. By this model, they believed that
the first hit was the presence of persistent “super
trypsin” within the acinar cell— the result of a loss of
balance between activation events and degradation of
active trypsin as a result of mutations in one or more of
the aforementioned genes. This would lead to inflammation in the gland. A second hit in the form of another
sequence of genetic mutations with/without environmental factors would then lead to the clinical disease
entity of TCP.

Epidemiology andPathophysiology ofTropical Chronic Pancreatitis
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
386
Table46.1 Gene mutations involved inthe pathogenesis ofTCP.
Gene mutation References
SPINK1
pN34S variant
Loss- of- function variant c.- 142T>C
CTSB
Polymorphism p.L26V
Polymorphism p.S53G
CTRC
c.217G>A (p.A73T) variant
c.703G>A (p.V235I) variant
Carboxypeptidase A1
p.D32H, p.R169H, and p.Y308H variants
Glycoprotein 2
c.1275A>G variant
Calcium-
SPINK1: serine protease inhibitor Kazal type 1; CTSB: cathepsin B;
CTRC: chymotrypsin C.
sensing receptor
p.P163R, p.I427S, p.D433H, p.V477A variants74
67, 69, 70, 84
68
71, 85
85
34
34
72
73
Natural History ofthe Disease
two mechanisms: the pathogenetic process of tissue
fibrosis eliciting CP, and a selective pancreatic beta-
cell
impairment [78]. TCP is associated with an increased
risk of pancreatic cancer development [79]. In a study
from Chennai (India), the relative risk of pancreatic cancer in patients with TCP was estimated to be significantly
high at 100 (95% CI: 37–218)[80].
In comparison to the initial reports of the dismal clinical course of TCP which resulted in death by early adulthood [22], a survival analysis of 370 patients in the
mid- 1990s determined that patients with TCP were living much longer than before[81] with 80% of patients
still alive 35 years from the onset of the first episode of
abdominal pain and a mean of 25 years from the diagnosis of diabetes mellitus. The causes of death in TCP
include diabetes- related complications, pancreatic cancer[82], and severe infections[24].
Garg and Narayana[83] have recently questioned the
need to consider TCP as a unique entity for multiple reasons, including its similarity to idiopathic CP down to
the genetic level, in addition to a significant decline in
the clinical picture that helped define this entity by the
incorrect use of the term “tropical,” which would normally be used for infectious diseases.
In the original reports of TCP, the disease was noted to
afflict young individuals between the ages of 10 and 30
years who also demonstrated features of protein and calorie malnutrition, along with bilateral parotid enlargement and occasionally a cyanotic hue to the lips[5,76].
They suffered from recurrent severe upper abdominal
pain radiating to the back that was relieved by bending
forward. In the ensuing years, it was noted that while
some patients developed features of pancreatic exocrine
insufficiency such as maldigestion and steatorrhea, others did not do so because of their low- fat diet. They
developed diabetes mellitus within 10–20 years from the
onset of the initial symptoms of pain [31]. Mohan and
colleagues [77] determined that the median time to
development of diabetes mellitus in patients with TCP
was 9.6 years from diagnosis and this was associated
with an older age, higher body mass index, and lower
fecal chymotrypsin level. The development of diabetes
mellitus in TCP has been hypothesized to result from
References
1 Kini M. Multiple pancreatic calculi with chronic
pancreatitis. Br J Surg 1937;25:705.
2 Elizabeth T, Stephen P. Pancreatic calculi. J Indian Med
Assoc 1954;24:126.
3 Zuidema PJ. Calcification and cirrhosis of the pancreas in
patients with deficient nutrition. Doc Med Geogr Trop
1955;7:229–251.
Conclusion
In conclusion, the incidence of TCP is on the decline
even in developing countries. The disease is witnessing a
paradigm shift in relation to a number of aspects including the reduced emphasis on macronutrient, protein
calorie malnutrition, and cassava ingestion as etiological
factors, in favor of micronutrient deficiency (including
zinc) and oxidant stress, an increased appreciation of the
role of gene mutations in the pathogenesis of the disease,
and finally, significantly improved survival, possibly as a
result of better management of the disease and its attendant complications. The mounting evidence calls for a
unified, evidencefraternity to clarify whether TCP should continue to
remain a unique entity, or be included under the broad
umbrella of idiopathic CP.
4 Zuidema PJ. Cirrhosis and disseminated calcification of the
pancreas in patients with malnutrition. Trop Geogr Med
1959;11:70–74.
5 GeeVarghese P. Calcific Pancreatitis. Causes and
Mechanisms in the Tropics Compared with Those in
the Subtropics. Bombay: Varghese Publishing House,
1986.
based approach by the pancreatology

References 387
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
6 GeeVarghese P, Pitchumoni C. Pancreatic diabetes in
Kerala. In: Patel J, Talwalkar N, eds. Diabetes in the
Tropics. Bombay: Diabetes Association of India, 1966:
233–239.
7 Ralapanawa DM, Jayawickreme KP, Ekanayake EM.
Fibrocalculous pancreatic diabetes: a case report. BMC
Res Notes 2015;8:175.
8 Balaji L, Tandon R, Tandon B, Banks P. Prevalence and
clinical features of chronic pancreatitis in southern India.
Int J Pancreatol 1994;15:29–34.
9 Garg P, Tandon R. Survey on chronic pancreatitis in the
Asia-
Pacific region. J Gastroenterol Hepatol 2004;19:
998–1004.
10 Rerknimitr R. Asian chronic pancreatitis: the common and
the unique. J Gastroenterol Hepatol 2011;26(Suppl 2):6–11.
11 Lin Y, Tamakoshi A, Matsuno S etal. Nationwide
epidemiological survey of chronic pancreatitis in Japan.
JGastroenterol 2000;35:136–141.
12 Shaper AG. Chronic pancreatic disease and protein
malnutrition. Lancet 1960;1:1223–1224.
13 Kinnear T. Patterns of diabetes in a Nigerian teaching
hospital. West Afr Med J 1963;40:228–233.
14 Mongola E. Diabetes mellitus in the African environment:
the dilemma. In: Mongola E, ed. Diabetes 1982,
Proceedings of the 2nd Congress of the IDF. Amsterdam:
Excerpta Medica, 1983: 309–313.
15 Osier FH, Newton CR. Fibrocalculous pancreatic diabetes
in a child: case report. East Afr Med J 1999;76:703–705.
16 Dani R, Nogueira CE. [Chronic calcifying pancreatitis in
Brazil: analysis of 92 cases (authors’ transl)]. Leber Magen
Darm 1976;6:272–275.
17 Dani R, Penna FJ, Nogueira CE. Etiology of chronic
calcifying pancreatitis in Brazil: a report of 329
consecutive cases. Int J Pancreatol 1986;1:399–406.
18 Chari ST, Mohan V, Jayanthi V etal. Comparative study of
the clinical profiles of alcoholic chronic pancreatitis and
tropical chronic pancreatitis in Tamil Nadu, South India.
Pancreas 1992;7:52–58.
19 Thomas PG, Augustine P, Ramesh H, Rangabashyam N.
Observations and surgical management of tropical
pancreatitis in Kerala and southern India. World J Surg
1990;14:32–42.
20 Khan AA, Ali L. Tropical calcific pancreatitis and
fibrocalculus pancreatic diabetes in Bangladesh. J
Gastroenterol Hepatol 1997;12: S48–52.
21 Jean Louis CC, Beaumont Caminos CC, Fernandez Esain
BB, Gimena Ramos I. Tropical pancreatitis: an unusual
case of chronic pancreatitis in juveniles. Am J Emerg Med
2008;26:731.e735–736.
22 Geevarghese P. Pancreatic Diabetes. Bombay: Popular
Prakashan, 1968: 110–115.
23 Mohan V, Premalatha G, Pitchumoni CS. Tropical chronic
pancreatitis: an update. J Clin Gastroenterol
2003;36:337–346.
24 Barman KK, Premalatha G, Mohan V. Tropical chronic
pancreatitis. Postgrad Med J 2003;79:606–615.
25 Balakrishnan V, Unnikrishnan AG, Thomas V etal.
Chronic pancreatitis. A prospective nationwide study of
1,086 subjects from India. JOP 2008;9:593–600.
26 Rajesh G, Girish BN, Panicker S, Balakrishnan V. Time
trends in the etiology of chronic pancreatitis in South
India. Trop Gastroenterol 2014;35:164–167.
27 Midha S, Khajuria R, Shastri S, Kabra M, Garg PK.
Idiopathic chronic pancreatitis in India: phenotypic
characterisation and strong genetic susceptibility due to
SPINK1 and CFTR gene mutations. Gut 2010;59:800–807.
28 Balakrishnan V, Nair P, Radhakrishnan L, Narayanan VA.
Tropical pancreatitis -
- a distinct entity, or merely a type of
chronic pancreatitis? Indian J Gastroenterol 2006;25:74–81.
29 Garg PK. Chronic pancreatitis in India and Asia. Curr
Gastroenterol Rep 2012;14:118–124.
30 McMillan D, GeeVarghese P. Dietary cyanide and tropical
malnutrition diabetes. Diabetes Care 1979;2:202–208.
31 Mohan V, Nagalotimath SJ, Yajnik CS, Tripathy BB.
Fibrocalculous pancreatic diabetes. Diabetes Metab Rev
1998;14:153–170.
32 Mohan V, Chari S, Ramachandran A etal. Fibrocalculous
pancreatic diabetes and obesity. Diabetes Res Clin Pract
1990;8:161–166.
33 Shrikhande SV, Martignoni ME, Shrikhande M etal.
Comparison of histological features and inflammatory cell
reaction in alcoholic, idiopathic and tropical chronic
pancreatitis. Br J Surg 2003;90:1565–1572.
34 Paliwal S, Bhaskar S, Mani KR etal. Comprehensive
screening of chymotrypsin C (CTRC) gene in tropical
calcific pancreatitis identifies novel variants. Gut
2013;62(11):1602–6.
35 Braganza JM, Schofield D, Snehalatha C, Mohan V.
Micronutrient antioxidant status in tropical compared
with temperate- zone chronic pancreatitis. Scand J
Gastroenterol 1993;28:1098–1104.
36 Nair B. Pathology of tropical calcific pancreatitis. In:
Kumar N, Acharya S, eds. Tropical Calcific Pancreatitis.
Kerala: Roussel Scientific Institute, 1994: 83–90.
37 Nagalotimath S. Pancreatic pathology in pancreatic
calcification with diabetes. In: Podolsky S, Viswanathan M,
eds. Secondary Diabetes: The Spectrum of Diabetic
Syndromes. NewYork: Raven Press, 1980: 117–145.
38 Schultz A, Moore P, Geevarghese P. X- ray diffraction
studies of pancreatic calculi associated with nutritional
pancreatitis. Dig Dis Sci 1986;31:476–480.
39 Pitchumoni CS, Viswanathan KV, Gee Varghese PJ, Banks
PA. Ultrastructure and elemental composition of human
pancreatic calculi. Pancreas 1987;2:152–158.
40 Sindhu R, Subhash R, Gireesan P etal. Scanning electron
microscopic analysis of pancreatic tissue in alcoholic and
tropical chronic pancreatitis. Pancreatology 2015;15:
226–232.
41 Cyriac J, Mahadevan P, Augustine P, Ramesh H, Koshy A.
Stellate cell activation in tropical calcific pancreatitis
compared to alcoholic pancreatitis, adenocarcinoma of
pancreas and normal pancreas. JOP 2012;13:376–386.

Epidemiology andPathophysiology ofTropical Chronic Pancreatitis
Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
https://t.me/medicina_free
388
42 Govindarajan M, Mohan V, Deepa R, Ashok S, Pitchumoni
CS. Histopathology and immunohistochemistry of
pancreatic islets in fibrocalculous pancreatic diabetes.
Diabetes Res Clin Pract 2001;51:29–38.
43 Friess H, Shrikhande S, Shrikhande M etal. Neural
alterations in surgical stage chronic pancreatitis are
independent of the underlying aetiology. Gut
2002;50:682–686.
44 Barreto S, Saccone G. Pancreatic nociception: revisiting
the physiology and pathophysiology. Pancreatology
2012;12:104–112.
45 Pitchumoni C: Special problems of tropical pancreatitis.
JClin Gastroenterol 1985;13:941–959.
46 Sathiaraj E, Gupta S, Chutke M etal. Malnutrition is not
an etiological factor in the development of tropical
pancreatitis-
- a case- control study of southern Indian
patients. Trop Gastroenterol 2010;31:169–174.
47 Regunath H, Shivakumar BM, Kurien A, Satyamoorthy K,
Pai CG. Anthropometric measurements of nutritional
status in chronic pancreatitis in India: comparison of
tropical and alcoholic pancreatitis. Indian J Gastroenterol
2011;30:78–83.
48 Midha S, Singh N, Sachdev V, Tandon R, Joshi Y, Garg P.
Cause and effect relationship of malnutrition with
idiopathic chronic pancreatitis: prospective case-
control
study. J Gastroenterol Hepatol 2008;23:1378–1383.
49 Balakrishnan V, Sauniere JF, Hariharan M, Sarles H. Diet,
pancreatic function, and chronic pancreatitis in South
India and France. Pancreas 1988;3:30–35.
50 Lester F. A search for malnutrition related diabetes
mellitus in an Ethiopian diabetes clinic. Bull Int Diabetes
Fed 1984;29:14.
51 Tinju J, Reshmi S, Rajesh G, Balakrishnan V.
Anthropometric, biochemical, clinical and dietary
assessment for malnutrition in South Indian patients with
chronic pancreatitis. Trop Gastroenterol 2010;31:285–290.
52 McMillan D, Geevarghese P. Dietary cyanide and tropical
malnutrition diabetes. In: Podolsky S, Viswanathan M,
eds. Secondary Diabetes: The Spectrum of the Diabetic
Syndrome. NewYork: Raven Press, 1980: 239–253.
53 Pitchumoni C, Jain N, Lowenfels A, DiMagno E. Chronic
cyanide poisoning: Unifying concept for alcoholic and
tropical pancreatitis. Pancreas 1988;3:220–222.
54 Kamalu B. The effect of a nutritionally- balanced cassava
(Manihot esculenta crantz) diet on endocrine function
using the dog as a model. 1. Pancreas. Br J Nutr
1991;65:365–372.
55 Girish BN, Rajesh G, Vaidyanathan K, Balakrishnan V.
Assessment of cassava toxicity in patients with tropical
chronic pancreatitis. Trop Gastroenterol 2011;32:112–116.
56 Narendranathan M, Cheriyan A. Lack of association
between cassava consumption and tropical pancreatitis
syndrome. J Gastroenterol Hepatol 1994;9:282–285.
57 Teuscher T, Baillod P, Rosman JB, Teuscher A. Absence of
diabetes in a rural West African population with a high
carbohydrate/cassava diet. Lancet 1987;1:765–768.
58 Mathangi D, Deepa R, Mohan V, Govindarajan M,
Namasivayam A. Long-
term ingestion of cassava (tapioca)
does not produce diabetes or pancreatitis in the rat model.
Int J Pancreatol 2000;27:203–208.
59 Braganza JM. A framework for the aetiogenesis of
chronic pancreatitis. Digestion 1998;59(Suppl 4):1–12.
60 Grigsby B, Rodriguez- Rilo H, Khan K. Antioxidants and
chronic pancreatitis: theory of oxidative stress and trials of
antioxidant therapy. Dig Dis Sci 2012;57:835–841.
61 Chaloner C, Sandle LN, Mohan V, Snehalatha C,
Viswanathan M, Braganza JM. Evidence for induction of
cytochrome p-
450i in patients with tropical chronic
pancreatitis. Int J Clin Pharmacol Ther Toxicol
1990;28:235–240.
62 Girish B, Rajesh G, Vaidyanathan K, Balakrishnan V.
Assessment of oxidative status in chronic pancreatitis and
its relation with zinc status. Indian J Gastroenterol
2011;30:84–88.
63 Girish B, Rajesh G, Vaidyanathan K, Balakrishnan V. Zinc
status in chronic pancreatitis and its relationship with
exocrine and endocrine insufficiency. JOP 2009;10: 651–656.
64 Rajesh G, Girish B, Vaidyanathan K, Balakrishnan V. Diet,
nutrient deficiency and chronic pancreatitis. Trop
Gastroenterol 2013;34: 68–73.
65 Pitchumoni C. Familial pancreatitis; In: Pai K, Soman C,
Varghese R eds. Pancreatic Diabetes. Trivandrum, India:
Geo Printers, 1970: 46–48.
66 Mohan V, Chari ST, Hitman GA etal. Familial aggregation
in tropical fibrocalculous pancreatic diabetes. Pancreas
1989;4: 690–693.
67 Aoun E, Chang CC, Greer JB, Papachristou GI, Barmada
MM, Whitcomb DC. Pathways to injury in chronic
pancreatitis: decoding the role of the high- risk
SPINK1n34s haplotype using meta-
analysis. PLoS ONE
2008;3:e2003.
68 Boulling A, Witt H, Chandak GR etal. Assessing the
pathological relevance of SPINK1 promoter variants. Eur J
Hum Genet 2011;19:1066–1073.
69 Chandak GR, Idris MM, Reddy DN, Bhaskar S, Sriram PV,
Singh L. Mutations in the pancreatic secretory trypsin
inhibitor gene (PSTI/SPINK1) rather than the cationic
trypsinogen gene (PRSS1) are significantly associated with
tropical calcific pancreatitis. J Med Genet 2002;39:347–351.
70 Chandak GR, Idris MM, Reddy DN etal. Absence of
PRSS1mutations and association of SPINK1 trypsin
inhibitor mutations in hereditary and non-
hereditary
chronic pancreatitis. Gut 2004;53:723–728.
71 Mahurkar S, Idris MM, Reddy DN etal. Association of
cathepsin B gene polymorphisms with tropical calcific
pancreatitis. Gut 2006;55:1270–1275.
72 Witt H, Beer S, Rosendahl J etal. Variants in cpa1 are
strongly associated with early onset chronic pancreatitis.
Nat Genet 2013;45:1216–1220.
73 Masson E, Paliwal S, Bhaskar S etal. Genetic analysis of
the glycoprotein 2 gene in patients with chronic
pancreatitis. Pancreas 2010;39:353–358.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
